• NanoM-17.jpg
  • photo BK.JPG
  • photo flow cell.jpg
  • photo staph.jpg



Infections caused by MDR TB and MRSA lead to serious diseases which usually require intensive care treatment with a long hospitalization. The portfolio of available antibiotics for treating antibiotic resistant bacterial infections is very limited and comprises molecules inducing severe side effects and/or difficult to administrate like aminoglycosides and vancomycin that require parenteral injection.

New drugs or at least new formulations of known drugs that provide better efficacy are urgently needed for faster, more efficient, and less impairing treatments.

The possibility of using novel drug delivery systems for known and new antibiotic drugs opens the way to an innovative management of infections caused by drug resistant bacteria, which are otherwise difficult to treat.

The successful use of nanoparticles for delivering and concentrating antimicrobial molecules to the site of infections should allow the use of antibiotics that have proved their efficiency in vitro but that show poor in vivo bioavailability.




The NAREB project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 604237.